Related Experiment Video
Updated: Sep 6, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Assessing the Frequency, Type, and Severity of Drug-Induced Liver Injury with Azole Antifungal Drugs for
Madiha Sajid1,2,3, Sabhita Shabir Shaikh, Shazia Siddiqui
1Department of Dermatology, Dow University Hospital, Dow University of Health Sciences, Ojha Campus, Karachi, Pakistan.
Objective:
To determine the frequency, nature, and severity of drug-induced liver injury (DILI) among patients receiving azole antifungal agents for superficial fungal skin infections.
Study Design:
A descriptive study. Place and Duration of the Study: Department of National Institute of Liver and Gastrointestinal Diseases, Dow University Hospital, Dow University of Health Sciences, Ojha Campus, Karachi, Pakistan, from July 2024 to January 2025.
Methodology:
A total of 116 patients were enrolled, and baseline liver function tests (LFTs) were performed at the start of treatment and repeated at 4 and 6 weeks. Those who developed deranged LFTs were referred to the hepatology clinic. Additional investigations were done for those who developed deranged LFTs. DILI was defined according to international criteria and classified using the R-value. The Wilcoxon signed-rank and Friedman tests were used for statistical analysis.
Results:
Among 116 patients with tinea corporis/cruris, 102 (87.9%) received itraconazole and 14 (12.1%) voriconazole. Liver function derangement occurred in 65 (56%) patients, of whom only 10 (8.6%) patients developed DILI, predominantly a cholestatic pattern. Six out of 10 DILI cases occurred among itraconazole-treated patients. A short-term (4-week) course showed significant increases in alkaline phosphatase (ALP) and aspartate aminotransferase (AST) levels (p = 0.012), whereas 6-week treatment led to marked increases in alanine aminotransferase (ALT), ALP, and AST levels (p <0.001).
Conclusion:
This study strengthens the association of azole antifungals with mild biochemical liver abnormalities and infrequent DILI. A short- term course of azoles causes a rise in ALP and AST, while longer courses cause a more comprehensive rise in LFTs. Thus, this highlights a time-dependent effect and necessitates regular monitoring of LFTs during and after treatment.
Key Words:
Drug-induced liver injury, Liver function tests, Azoles, Dermatophytosis, Tinea corporis/cruri, R-value, Cholestasis.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Antifungal Agents
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Therapeutic Drug Monitoring: Affecting Factors
